A.R.T. Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

A.R.T. Advisors’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16,854	Closed	-$235K	–	1798
2018 Q3	$235K	Buy	+16,854	New	+$228K	0.01%	1134
2017 Q4	–	Sell	-15,900	Closed	-$124K	–	1786
2017 Q3	$124K	Sell	15,900 -4,400	-22%	-$33K	0.01%	1195
2017 Q2	$174K	Buy	+20,300	New	+$146K	0.01%	1188
2016 Q1	–	Sell	-10,474	Closed	-$35K	–	1752
2015 Q4	$35K	Buy	+10,474	New	+$48.6K	﹤0.01%	1397
2015 Q3	–	Sell	-11,998	Closed	-$81K	–	1703
2015 Q2	$81K	Sell	11,998 -11,397	-49%	-$80.8K	﹤0.01%	1384
2015 Q1	$167K	Sell	23,395 -12,672	-35%	-$87.3K	0.01%	1263
2014 Q4	$268K	Buy	36,067 +19,758	+121%	+$168K	0.01%	1138
2014 Q3	$150K	Buy	+16,309	New	+$220K	0.01%	1156

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's KIN Position: Q4 2018 in Review

A.R.T. Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q4 2018, closing a stake of 16,854 shares — an estimated $235K sold.

A.R.T. Advisors first reported a position in KIN in Q3 2014 and held it in 8 quarters. The position peaked at $268K in Q4 2014. 72 funds tracked by Wall St. Rank hold KIN as of Q4 2018.

A.R.T. Advisors reported no remaining Kindred Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
A.R.T. Advisors sold 16,854 Kindred Biosciences, Inc. shares in Q4 2018, an estimated $235K.
A.R.T. Advisors first reported a position in Kindred Biosciences, Inc. in Q3 2014 and held it in 8 quarters.
A.R.T. Advisors's Kindred Biosciences, Inc. position peaked at $268K in Q4 2014.
72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.